New CAR-T therapy targets Hard-to-Treat blood cancers in early trial
NCT ID NCT07365059
First seen Jan 29, 2026 · Last updated Jun 15, 2026 · Updated 19 times
Summary
This early-phase study tests a new type of CAR-T cell therapy (GPRC5D) in 18 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The goal is to see if the therapy is safe and can shrink or control the cancer. Researchers will also track how long the modified cells stay in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL DYSCRASIAS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.